FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13s - 16 or 15d - 16 of
the Securities Exchange Act of 1934
For the month of April 2007
Acambis plc
(Translation of registrant's name into English)
Peterhouse Technology Park
100 Fulbourn Road
Cambridge CB1 9PT
England
(address of principal executive offices)
(Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F
Forms 20-F X Form 40-F
Indicate by check mark whether the registrant by furnishing the information
contained in this Form also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934).
Yes No X
(if "Yes" is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g3-2(b): 82- ).
Enclosure:
1. Total Voting Rights dated 30 March 2007
2. Holding(s) in Company dated 02 April 2007
3. Advisory Committee meeting dated 17 April 2007
4. Holding(s) in Company dated 20 April 2007
5. Notice of Results dated 27 April 2007
Enclosure 1
Voting rights and capital
Cambridge, UK and Cambridge, Massachusetts - 30 March 2007 - Acambis plc
("Acambis") (LSE: ACM), in conformity with the Financial Services Authority's
("FSA") Transparency Directive, notifies that on 30 March 2007 Acambis' share
capital consisted of 107,671,341 ordinary 10p shares, each share having equal
voting rights.
This figure may be used by shareholders as the denominator for the calculations
by which they will determine if they are required to notify their interest in,
or a change to their interest in, Acambis under the FSA's Disclosure and
Transparency Rules.
-ends-
Enquiries:
Acambis plc
Lyndsay Wright, VP, Communications and IR
Elizabeth Brown, Company Secretary
Tel: +44 (0 1223 275 300
About Acambis
Acambis is a leading biotechnology company targeting infectious diseases with
novel vaccines. Acambis' development-stage pipeline includes vaccines that could
either offer improvements over existing products or target unmet medical needs.
As well as ChimeriVax-JE, Acambis' proprietary ChimeriVax technology, developed
in association with St Louis University, has also been used to develop
ChimeriVax-West Nile, which is undergoing Phase 2 clinical testing, making it
the most advanced investigational vaccine against the West Nile virus. Acambis
also has the only vaccine in development against Clostridium difficile bacteria,
a leading cause of hospital-acquired infections. Recognised internationally as
the leading producer of smallpox vaccines, Acambis is developing an
investigational smallpox vaccine, ACAM2000, and is manufacturing emergency-use
stockpiles of this investigational vaccine for the US Government and other
governments around the world.
Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US, and is
listed on the London Stock Exchange (ACM). More information is available at
www.acambis.com.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of
1995:
The statements in this news release that are not historical facts are
forward-looking statements that involve risks and uncertainties, including the
timing and results of clinical trials, product development, manufacturing and
commercialisation risks, the risks of satisfying the regulatory approval process
in a timely manner, the need for and the availability of additional capital. For
a discussion of these and other risks and uncertainties see "Risk management" in
the Company's 2005 Annual Report and "Risk factors" in its Form 20-F, in
addition to those detailed on the Company's website and in the Company's filings
made with the Securities and Exchange Commission from time to time. These
forward-looking statements are based on estimates and assumptions made by the
management of Acambis and are believed to be reasonable, though are inherently
uncertain and difficult to predict. Actual results or experience could differ
materially from the forward-looking statements.
Enclosure 2
SCHEDULE 10
NOTIFICATION OF MAJOR INTERESTS IN SHARES
1. Name of company
Acambis plc
2. Name of shareholder having a major interest
AMVESCAP PLC
3. Please state whether notification indicates that it is in respect of holding
of the shareholder named in 2 above or in respect of a non-beneficial interest
or in the case of an individual holder if it is a holding of that person's
spouse or children under the age of 18
As above
4. Name of the registered holder(s) and, if more than one holder, the number of
shares held by each of them
Vidacos Nominees 24,107,441 shares
HSBC Nominees 145,580 shares
Chase Bank 113,429 shares
Chase Nominees 381,629 shares
Bank of New York 122,899 shares
Bank of New York (Brussels) 38,910 shares
Bank of Ireland (Dublin) 350,836 shares
Mellon Bank (Pittsburg) 365,000 shares
Japan Trustee Services Bank 4,034 shares
State Street Trust and Banking, London 4,920,000 shares
Trust and Custody Services 6,631 shares
Northern Trust Company, London 618,676 shares
5. Number of shares / amount of stock acquired
N/A
6. Percentage of issued class
N/A
7. Number of shares / amount of stock disposed
Not disclosed
8. Percentage of issued class
Not disclosed
9. Class of security
Ordinary shares of 10p each
10. Date of transaction
28 March 2007
11. Date company informed
29 March 2007
12. Total holding following this notification
31,175,065 shares
13. Total percentage holding of issued class following this notification
28.95%
14. Any additional information
None
15. Name of contact and telephone number for queries
Elizabeth Brown, Company Secretary
+44 (0) 1223 275 300
16. Name and signature of authorised company official responsible for making
this notification
Elizabeth Brown
Date of notification
2 April 2007
The FSA does not give any express or implied warranty as to the accuracy of this
document or material and does not accept any liability for error or omission.
The FSA is not liable for any damages (including, without limitation, damages
for loss of business or loss of profits) arising in contract, tort or otherwise
from the use of or inability to use this document, or any material contained in
it, or from any action or decision taken as a result of using this document or
any such material.
Enclosure 3
FDA Advisory Committee meeting date confirmed for ACAM2000 review
Cambridge, UK and Cambridge, Massachusetts - 17 April 2007 - Acambis plc
(Acambis) (LSE: ACM) announces that the US Food and Drug Administration's (FDA)
Vaccines and Related Biological Products Advisory Committee (the Advisory
Committee) will review Acambis' ACAM2000 smallpox vaccine on 17 May 2007.
At the meeting, the Advisory Committee will make recommendations to the FDA,
including an assessment of the safety and efficacy data generated as part of
ACAM2000 clinical programme. Acambis developed ACAM2000 under contracts with the
US Government and filed its Biologics License Application (BLA) in 2006. In
March 2007, Acambis provided the additional information requested by the FDA in
a Complete Response Letter issued to the Company in January 2007. The FDA has
notified Acambis that the additional information provided is complete and has
identified 31 August 2007 as the new Prescription Drug User Fee Act date, which
is the target date for the FDA's licence application response for ACAM2000.
-ends-
Enquiries:
Acambis plc
Gordon Cameron, Chief Executive Officer
Lyndsay Wright, VP, Communications and IR
Tel: +44 (0) 1223 275 300
Brunswick
Jon Coles / Justine McIlroy / Margherita Lupi
Tel: +44 (0) 20 7404 5959
About the Vaccines and Related Biological Products Advisory Committee
The Advisory Committee advises the Commissioner of Food and Drugs in discharging
responsibilities as they relate to helping to ensure safe and effective
biological products, and, as required, any other product for which the FDA has
regulatory responsibility. The Advisory Committee reviews and evaluates data
concerning the safety, effectiveness and appropriate use of vaccines and related
biological products that are intended for use in the prevention, treatment, or
diagnosis of human diseases, and, as required, any other product for which the
FDA has regulatory responsibility.
The Committee consists of a core of voting members including the Chair. Members
and the Chair are selected from among authorities knowledgeable in the fields of
immunology, molecular biology, rDNA, virology, bacteriology, epidemiology or
biostatistics, allergy, preventive medicine, infectious diseases, paediatrics,
microbiology and biochemistry. The core of voting members may include one
technically qualified member who is identified with consumer interests and is
recommended by either a consortium of consumer-oriented organisations or other
interested persons. In addition to the voting members, the Committee may also
include one non-voting member who is identified with industry interests.
Transcripts and related documents from the meeting will be published on the
Advisory Committee's website
(http://www.fda.gov/cber/advisory/vrbp/vrbpmain.htm).
About ACAM2000
Acambis currently supplies ACAM2000, its investigational smallpox vaccine to
governments, under a US FDA Investigational New Drug (IND) application. To date,
Acambis has supplied more than 200 million doses of ACAM2000 to 15 governments.
- ACAM2000 is derived from Dryvax(R), a first-generation vaccine used
during the global eradication programme
- It is manufactured using modern cell-culture techniques, designed to
comply with current Good Manufacturing Practice (GMP) standards
- It is a clonal vaccine - based on a single type of vaccinia virus which
has been well characterised
- It is routinely manufactured under animal serum-free conditions to
minimise the chance of any passenger viruses or animal proteins being
present
- It is grown in a continuous cell line providing a predictable,
standardised manufacturing process
- It has completed Phase 1, 2 and 3 clinical testing under an IND from the
US FDA
- A Biologics License Application (BLA) was filed with the FDA in 2006.
About Acambis
Acambis is a leading biotechnology company targeting infectious diseases with
novel vaccines. Acambis' development-stage pipeline includes vaccines that could
either offer improvements over existing products or target unmet medical needs.
ChimeriVax-JE, Acambis' most advanced product in the non-biodefence pipeline,
has to date shown an excellent safety and efficacy profile following pivotal
Phase 3 trials. It is currently undergoing paediatric trials in India and is
partnered with sanofi pasteur and Bharat Biotech. Acambis' proprietary
ChimeriVax technology, developed in association with St Louis University, has
also been used to develop ChimeriVax-West Nile, which is undergoing Phase 2
clinical testing, making it the most advanced investigational vaccine against
the West Nile virus. Acambis also has the only vaccine in development against
Clostridium difficile bacteria, a leading cause of hospital-acquired infections.
Recognised internationally as the leading producer of smallpox vaccines, Acambis
is developing an investigational smallpox vaccine, ACAM2000, and is
manufacturing emergency-use stockpiles of this investigational vaccine for the
US Government and other governments around the world.
Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US, and is
listed on the London Stock Exchange (ACM). More information is available at
www.acambis.com.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of
1995:
The statements in this news release that are not historical facts are
forward-looking statements that involve risks and uncertainties, including the
timing and results of clinical trials, product development, manufacturing and
commercialisation risks, the risks of satisfying the regulatory approval process
in a timely manner, the need for and the availability of additional capital. For
a discussion of these and other risks and uncertainties see "Risk management" in
the Company's 2005 Annual Report and "Risk factors" in its Form 20-F, in
addition to those detailed on the Company's website and in the Company's filings
made with the Securities and Exchange Commission from time to time. These
forward-looking statements are based on estimates and assumptions made by the
management of Acambis and are believed to be reasonable, though are inherently
uncertain and difficult to predict. Actual results or experience could differ
materially from the forward-looking statements.
Enclosure 4
SCHEDULE 10
NOTIFICATION OF MAJOR INTERESTS IN SHARES
1. Name of company
Acambis plc
2. Name of shareholder having a major interest
AMVESCAP PLC
3. Please state whether notification indicates that it is in respect of holding
of the shareholder named in 2 above or in respect of a non-beneficial interest
or in the case of an individual holder if it is a holding of that person's
spouse or children under the age of 18
As above
4. Name of the registered holder(s) and, if more than one holder, the number of
shares held by each of them
Vidacos Nominees 23,254,961 shares
HSBC Nominees 145,580 shares
Chase Bank 113,429 shares
Chase Nominees 114,980 shares
Bank of New York 122,899 shares
Bank of New York (Brussels) 38,910 shares
Bank of Ireland (Dublin) 350,836 shares
Mellon Bank (Pittsburg) 365,000 shares
Japan Trustee Services Bank 4,034 shares
State Street Trust and Banking, London 4,920,000 shares
Trust and Custody Services 6,631 shares
Northern Trust Company, London 611,285 shares
5. Number of shares / amount of stock acquired
N/A
6. Percentage of issued class
N/A
7. Number of shares / amount of stock disposed
Not disclosed
8. Percentage of issued class
Not disclosed
9. Class of security
Ordinary shares of 10p each
10. Date of transaction
17 April 2007
11. Date company informed
20 April 2007
12. Total holding following this notification
30,048,545 shares
13. Total percentage holding of issued class following this notification
27.91%
14. Any additional information
None
15. Name of contact and telephone number for queries
Elizabeth Brown, Company Secretary
+44 (0) 1223 275 300
16. Name and signature of authorised company official responsible for making
this notification
Elizabeth Brown
Date of notification
20 April 2007
The FSA does not give any express or implied warranty as to the accuracy of this
document or material and does not accept any liability for error or omission.
The FSA is not liable for any damages (including, without limitation, damages
for loss of business or loss of profits) arising in contract, tort or otherwise
from the use of or inability to use this document, or any material contained in
it, or from any action or decision taken as a result of using this document or
any such material.
Enclosure 5
Notice of results
Cambridge, UK and Cambridge, Massachusetts - 27 April 2007 - Acambis plc
("Acambis") (LSE: ACM) will announce its results for the first quarter ended 31
March 2007 on Thursday, 10 May 2007.
The results announcement will be released at 7.00 a.m. BST. A conference call
for analysts will be held at 9.00 a.m. BST. For details, please contact
Brunswick on telephone number +44 (0) 20 7404 5959.
An instant replay of the conference call will be available from 11.00 a.m. BST
on Thursday, 10 May 2007 for one week. The UK dial-in number for this replay is
+44 (0) 20 8196 1998 and the US dial-in number is +1 866 583 1035. The pin code
is 949716#.
A webcast of the call will also be available via Acambis' website at
www.acambis.com. The webcast replay will be available for 12 months until 10 May
2008.
-ends-
Enquiries:
Acambis plc
Lyndsay Wright, VP, Communications and Investor Relations
Tel: +44 (0) 1223 275 300
Brunswick
Jon Coles / Justine McIlroy / Margherita Lupi
Tel: +44 (0) 20 7404 5959
About Acambis
Acambis is a leading biotechnology company targeting infectious diseases with
novel vaccines. Acambis' development-stage pipeline includes vaccines that could
either offer improvements over existing products or target unmet medical needs.
ChimeriVax-JE, Acambis' most advanced product in the non-biodefence pipeline,
has to date shown an excellent safety and efficacy profile following pivotal
Phase 3 trials. It is currently undergoing paediatric trials in India and is
partnered with sanofi pasteur and Bharat Biotech. Acambis' proprietary
ChimeriVax technology, developed in association with St Louis University, has
also been used to develop ChimeriVax-West Nile, which is undergoing Phase 2
clinical testing, making it the most advanced investigational vaccine against
the West Nile virus. Acambis also has the only vaccine in development against
Clostridium difficile bacteria, a leading cause of hospital-acquired infections.
Recognised internationally as the leading producer of smallpox vaccines, Acambis
is developing an investigational smallpox vaccine, ACAM2000, and is
manufacturing emergency-use stockpiles of this investigational vaccine for the
US Government and other governments around the world.
Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US, and is
listed on the London Stock Exchange (ACM). More information is available at
www.acambis.com.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of
1995:
The statements in this news release that are not historical facts are
forward-looking statements that involve risks and uncertainties, including the
timing and results of clinical trials, product development, manufacturing and
commercialisation risks, the risks of satisfying the regulatory approval process
in a timely manner, the need for and the availability of additional capital. For
a discussion of these and other risks and uncertainties see "Risk management" in
the Company's 2005 Annual Report and "Risk factors" in its Form 20-F, in
addition to those detailed on the Company's website and in the Company's filings
made with the Securities and Exchange Commission from time to time. These
forward-looking statements are based on estimates and assumptions made by the
management of Acambis and are believed to be reasonable, though are inherently
uncertain and difficult to predict. Actual results or experience could differ
materially from the forward-looking statements.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant Peptide Therapeutics Group has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized.
Date: 29 April 2007 ACAMBIS PLC
By: /s/ Lyndsay Wright
Name: Lyndsay Wright
Title: VP, Communications and IR.